U.S. Markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.58+2.08 (+8.85%)
At close: 4:00PM EDT
25.58 0.00 (0.00%)
After hours: 06:45PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.50
Open23.51
Bid25.58 x 800
Ask26.49 x 3100
Day's Range23.47 - 26.08
52 Week Range18.16 - 36.48
Volume1,736,203
Avg. Volume806,804
Market Cap1.536B
Beta (5Y Monthly)2.29
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.78
  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX

    NEW YORK, NY / ACCESSWIRE / June 18, 2021 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX).

  • MacroGenics, Inc. Investors: Company Investigated by the Portnoy Law Firm
    GlobeNewswire

    MacroGenics, Inc. Investors: Company Investigated by the Portnoy Law Firm

    Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss

  • MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal
    Benzinga

    MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal

    MacroGenics Inc (NASDAQ: MGNX) and Zai Lab Limited (NASDAQ: ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules. The first collaboration program covers a lead research molecule that incorporates MacroGenics' DART platform and binds CD3 and an undisclosed target expressed in multiple solid tumors. The second collaboration program will cover a target to be designated by MacroGenics. Zai receives commercial rights in Greater China,